home / stock / biov:cc / biov:cc news


BIOV:CC News and Press, Biovaxys Technology Corp. From 06/08/22

Stock Information

Company Name: Biovaxys Technology Corp.
Stock Symbol: BIOV:CC
Market: CNQC
Website: biovaxys.com

Menu

BIOV:CC BIOV:CC Quote BIOV:CC Short BIOV:CC News BIOV:CC Articles BIOV:CC Message Board
Get BIOV:CC Alerts

News, Short Squeeze, Breakout and More Instantly...

BIOV:CC - Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study

Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study Canada NewsWire VANCOUVER, BC , June 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), anno...

BIOV:CC - BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program

BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program Canada NewsWire Pan-Sarbecovirus Vaccines Identified by WHO as a Critical Need VANCOUVER, BC , June 3, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (F...

BIOV:CC - Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30 years, researchers have been looking into the potenti...

BIOV:CC - BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement Canada NewsWire VANCOUVER, BC , May 18, 2022 /CNW/ -- BioVaxys Technology Corp. ( CSE: BIOV; FRA: 5LB; ...

BIOV:CC - International Patent Application Filed for Cervical Cancer Vaccine

International Patent Application Filed for Cervical Cancer Vaccine Canada NewsWire VANCOUVER, BC , May 2, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has continued to exp...

BIOV:CC - BIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS

BIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS Canada NewsWire VANCOUVER , BC , April 29, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF ) ("BioVaxys" or the "Company") is pleased to announce that Mr. Anthony Dutton...

BIOV:CC - Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating

Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer remains undetected until the mutation spreads to the stomach ...

BIOV:CC - BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction

Vancouver, BC – April 25, 2022 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered into an agreement with the Deaconess Research Institute (“DRI”) to supply BioVa...

BIOV:CC - The Power Play by The Market Herald Releases Interviews With Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp.

VANCOUVER, BC / ACCESSWIRE / March 30, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp. on their latest news. The Power ...

BIOV:CC - BioVaxys Expands Cancer Vaccine Platform

BioVaxys Expands Cancer Vaccine Platform Canada NewsWire BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC , March 30, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ( "BioVaxys" ...

Previous 10 Next 10